The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a new study finds, even though there’s little information on the drugs’ safety ...
A majority of people with overweight or obesity prescribed glucagon-like peptide 1 receptor agonists (GLP-1 RAs) discontinue them within 1 year, with higher quit rates among those without type 2 ...
One in eight American adults have used a GLP-1 agonist. This class of drugs are prescribed for weight loss, to treat diabetes, and to reduce the risk of heart attack and stroke in adults with heart ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results